Physician profile
David Appel
NPI 1235523325
$299.32
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $111.12 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $37.62 | 2019 | |
| Neos Therapeutics, LP | $36.65 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $19.17 | 2020 | |
| Lundbeck LLC | $18.85 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.63 | 2019 | |
| Adlon Therapeutics L.P. | $16.07 | 2020 | |
| Shire North American Group INC | $14.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.